Robert Avery - Profile and Journalist Details

Find journalists that align with your industry, location and vision. Unlock Robert Avery's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.

Get connected with journalists today
Robert Avery

Robert Avery

Verified

Sports Reporter, Chron

Final Covers

Culture , Current Events , Sports , Basketball , Nba

Journalist Type

Seniority Positions

Industries

Medium Formats

Content

Total articles 3918

  • Gene therapy for AMD: better as an adjuvant than a replacement - Authors' reply

    By Peter A Campochiaro, Robert Avery Verified, David Brown| The Lancet Verified We thank Huixun Jia and Xiaodong Sun for their perspective on our study.1 The goals of this first-in-human trial were to identify safe doses of RGX-314 and an optimised protocol for advanced studies. Doses in cohorts 1 and 2 were very low, resulting in little expression of anti-vascular endothelial growth factor (VEGF) protein, and, reassuringly, supplemental anti-VEGF injections were needed (these cohorts were vector-treated controls).

    By Peter A Campochiaro, Robert Avery Verified, David Brown · The Lancet

    Mar. 06, 2025

  • Patriots nab Region III title

    By Robert Avery Verified| Baytown Sun Verified The best-dressed high school soccer coach now oversees one of the best teams in Texas. For the second time in the last three postseason matches, Goose Creek Memorial’s soccer team overcame a 1-0 halftime deficit, riding an Issac Paramo goal in overtime that lifted the team to a dramatic and emotional 2-1 Region III-5A championship-clinching win over Magnolia West at Turner Stadium Saturday afternoon.

    By Robert Avery Verified · Baytown Sun

    Apr. 08, 2024

  • Gene therapy for AMD: better as an adjuvant than a replacement - Authors' reply

    By Peter A Campochiaro, Robert Avery Verified, David Brown| The Lancet Verified We thank Huixun Jia and Xiaodong Sun for their perspective on our study.1 The goals of this first-in-human trial were to identify safe doses of RGX-314 and an optimised protocol for advanced studies. Doses in cohorts 1 and 2 were very low, resulting in little expression of anti-vascular endothelial growth factor (VEGF) protein, and, reassuringly, supplemental anti-VEGF injections were needed (these cohorts were vector-treated controls).

    By Peter A Campochiaro, Robert Avery Verified, David Brown · The Lancet

    Mar. 06, 2025

As seen in

Company Info

Chron

Houston Chronicle is an online platform that publishes regional, business, sports and entertainment news.

'+1 713-362-7171

Founded: 1901